WEBTRODELVY is a Trop-2-directed ADC approved for metastatic breast, triple-negative breast, and urothelial cancers. See package insert for indications, dosing, safety information, and more resources.
WEBTRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate for breast and urothelial cancer. See dosage, warnings, adverse reactions, and more in … File Size: 854KB Page Count: 29
WEBTRODELVY is a prescription medicine for adults with certain types of breast and urinary tract cancers. It can cause serious side effects, such as low white blood cell … File Size: 117KB Page Count: 3
File Size: 117KB
Page Count: 3
DA:50PA:47MOZ Rank:54Up or Down:Up
TRODELVY® (sacituzumab govitecan-hziy) | Official …
WEBTRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate for mTNBC. See prescribing information, including boxed warning, indications, adverse reactions, and drug interactions.
WEBTRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: …
WEBThis document provides health professional information on TRODELVY, a monoclonal antibody-drug conjugate for the treatment of metastatic breast cancer. It includes …
WEB2 DOSAGE AND ADMINISTRATION. 2.1 Important Dosing Information. Premedicate before each infusion [see Dosage and Administration (2.4)]. Provide prophylactic hydration and …
DA:5PA:19MOZ Rank:67Up or Down:Up
Dosing Information | TRODELVY® (sacituzumab govitecan-hziy)
WEBTRODELVY ® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone …
WEBTRODELVY was administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles at doses of 10 mg/kg until disease progression or …